A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Summary

The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly rash).

Timeline

Start

2017-11-02

Primary completion

2018-06-26

Completion

2018-06-26

Outcome

Outcome not reported

Stopped: “Adverse change in the risk/benefit”

Drugs

Indications